所长
邵志敏 教授
教授,博士生导师
E-mail: zhiminshao@yahoo.com
 

  邵志敏教授,首批教育部长江学者特聘教授,复旦特聘教授。现任复旦大学肿瘤研究所所长,乳腺癌研究所所长,大外科主任兼乳腺外科主任,中国抗癌协会乳腺癌专业委员会名誉主委,中华医学会肿瘤学分会副主任委员,上海市抗癌协会乳腺癌专业委员会名誉主任委员,上海市医学会肿瘤专科委员会主任委员,第八届亚洲乳腺癌协会主席,St. Gallen乳腺癌大会专家团成员。主要从事乳腺癌的临床和基础研究,建立适合中国人群的早期筛查和诊疗流程,开展临床试验提高乳腺癌患者的预后,科研重点为乳腺癌的转化研究和乳腺癌转移机制研究等。已发表有关乳腺癌研究的论著近350篇,其中SCI收录100余篇,被世界医学文献引用逾3000次,主编专著4本。并多次获得卫生部科技进步一等奖,上海市科技进步一、二、三等奖,国家科技进步二等奖,教育部科技进步一、二等奖,领衔团队分别入选教育部创新团队、上海市乳腺肿瘤重点实验室及上海市教委“重中之重临床医学中心B类”项目、上海市重要疾病联合攻关项目。先后主持国家杰青基金、国自然、十五攻关课题、卫生部临床重点项目、211工程II、985、973课题及其他省部级项目30余项。


研究领域:

  主要从事乳腺癌的临床和基础研究,建立适合中国人群的早期筛查和诊疗流程,开展临床试验提高乳腺癌患者的预后;科研重点为乳腺癌的转化研究和乳腺癌转移机制研究等。

研究团队:



代表性论著:

  1. Ye FG, Song CG, Cao ZG, Xia C, Chen DN, Chen L, Li S, Qiao F, Ling H, YaoL, HuX, Shao ZM*. Cytidine Deaminase Axis Modulated by miR-484 Differentially Regulates Cell Proliferation and Chemoresistance in Breast Cancer. Cancer Res, 2015 Apr 1; 75(7):1504-15.
  2. Hu XC, Zhang J, Xu BH, Cai L, Ragaz J, Wang ZH, Wang BY, Teng YE, Tong ZS, Pan YY, Yin YM, Wu CP, Jiang ZF, Wang XJ, Lou GY, Liu DG, Feng JF, Luo JF, Sun K, Gu YJ, Wu J, Shao ZM*. Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first-line therapy for metastatic triple-negative breast cancer (CBCSG006): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncol, 2015 Apr; 16(4):436-46.
  3. Yu KD, Shao ZM*. Survival benefit from response-guided approach: a direct effect of more effective cytotoxic regimens or an indirect effect of chemotherapy-induced amenorrhea? J Clin Oncol, 2014 Apr 20; 32(12):1282-3.
  4. Jiang YZ, Yu KD, Bao J, Peng WT, Shao ZM*. Favorable prognostic impact in loss of TP53 and PIK3CA mutations after neoadjuvant chemotherapy in breast cancer. Cancer Res, 2014 Jul 1; 74(13):3399-407.
  5. Jiang YZ, Yu KD, Peng WT, Di GH, Wu J, Liu GY, Shao ZM*. Enriched variations in TEKT4 and breast cancer resistance to paclitaxel. Nat Commun, 2014 May 13; 5:3802.
  6. Fan L, Strasser-Weippl K, Li JJ, St Louis J, Finkelstein DM, Yu KD, Chen WQ, Shao ZM*, Goss PE. Breast cancer in China. Lancet Oncol, 2014 Jun; 15(7):e279-89.
  7. Qian GW, Ni XJ, Wang Z, Jiang YZ, Yu KD, Shao ZM*. Effect of radiotherapy on survival of women with locally excised ductal carcinoma in situ of the breast: a Surveillance, Epidemiology, and End Results population-based analysis. Onco Targets Ther, 2015 Jun 10; 8:1407-18.
  8. YuKD, JiangYZ, ShaoZM*. Difference between observed and expected number of involved lymph nodes reflects the metastatic potential of breast cancer independent to intrinsic subtype. Oncotarget, 2015 Jun 30; 6(18):16686-97.
  9. LiuYR, JiangYZ, YuKD, Shao ZM*. Different patterns in the prognostic value of age for breast cancer-specific mortality depending on hormonereceptor status: a SEER population-based analysis. AnnSurgOncol, 2015 Apr; 22(4):1102-10.
  10. Chen DN, Song CG, Ouyang QW, Jiang YZ, Ye FG, Ma FJ, Luo RC, ShaoZM*. Differences in breast cancer characteristics and outcomes between Caucasian and Chinese women in the US. Oncotarget, 2015 May 20; 6(14):12774-82.
  11. ChenS, LiuY, OuyangQW, HuangL, LuoRC, Shao ZM*. Clinical and pathological response to neoadjuvant chemotherapy based on primary tumor reduction is correlated to survival in hormone receptor-positive but not hormone receptor-negative locally advanced breast cancer. AnnSurgOncol, 2015 Jan; 22(1):32-9.
  12. ChenDN, SongCG, YuKD, JiangYZ, YeFG, ShaoZM*. A Prospective Evaluation of the Association between a Single Nucleotide Polymorphism rs3775291 in Toll-Like Receptor 3 and Breast Cancer Relapse. PLoS One, 2015 Jul 30; 10(7):e0133184.
  13. ChenS, HuangL, ChenCM, ShaoZM*. Progesterone receptor loss identifies luminal-type local advanced breast cancer with poor survival in patients who fail to achieve a pathological complete response to neoadjuvant chemotherapy. Oncotarget, 2015 Jul 20; 6(20):18174-82.
  14. Yang L, Yu SJ, Hong Q, Yang Y, Shao ZM*. Reduced Expression of TET1, TET2, TET3 and TDG mRNAs Are Associated with Poor Prognosis of Patients with Early Breast Cancer. PLoS One, 2015 Jul 24; 10(7):e0133896.
  15. Hao S, Liu Y, Yu KD, Chen S, Yang WT, Shao ZM*. Overweight as a Prognostic Factor for Triple-Negative Breast Cancers in Chinese Women. PLoS One, 2015 Jun 24; 10(6):e0129741.
  16. Wang L, Yao L, Zheng YZ, Xu Q, Liu XP, Hu X, Wang P, Shao ZM*. Expression of autophagy-related proteins ATG5 and FIP200 predicts favorable disease-free survival in patients with breast cancer. Biochem Biophys Res Commun, 2015 Mar 20; 458(4):816-22.
  17. Yu SJ, Hu JY, Kuang XY, Luo JM, Hou YF, Di GH, Wu J, Shen ZZ, Song HY, Shao ZM*. MicroRNA-200a promotes anoikis resistance and metastasis by targeting YAP1 in human breast cancer. Clin Cancer Res, 2013 Mar 15; 19(6):1389-99.
  18. Yu KD, Zhu R, Zhan M, Rodriguez AA, Yang W, Wong S, Makris A, Lehmann BD, Chen X, Mayer I, Pietenpol JA, Shao ZM, Symmans WF, Chang JC. Identification of prognosis-relevant subgroups in patients with chemoresistant triple-negative breast cancer. Clin Cancer Res, 2013 May 15; 19(10):2723-33.
  19. Sheng Chen, Yi-Zhou Jiang, Liang Huang, Ruo-Ji Zhou, Ke-Da Yu, Yin Liu, Zhi-Ming Shao*. The Residual Tumor Autophagy Marker LC3B Serves as a Prognostic Marker in Local Advanced Breast Cancer after Neoadjuvant Chemotherapy. Clin Cancer Res, 2013 Dec 15; 19(24):6853-62. 
  20. Yu KD, Wu J, Shen ZZ, Shao ZM*. Hazard of breast cancer-specific mortality among women with estrogen receptor-positive breast cancer after five years from diagnosis: implication for extended endocrine therapy. J Clin Endocrinol Metab, 2012 Dec; 97(12):E2201-9. 
  21. Yu KD, Shao ZM*. Initiation, evolution, phenotype and outcome of BRCA1 and BRCA2 mutation-associated breast cancer. Nat Rev Cancer, 2012 May 24; 12(5):372-3.
  22. Yu KD, Jiang YZ, Chen S, Cao ZG, Wu J, Shen ZZ, Shao ZM*. Effect of large tumor size on cancer-specific mortality in node-negative breast cancer. Mayo Clin Proc, 2012 Dec; 87(12):1171-80. 
  23. Yu KD, Huang AJ, Fan L, Li WF, Shao ZM*. Genetic variants in oxidative stress-related genes predict chemoresistance in primary breast cancer: a prospective observational study and validation. Cancer Res, 2012 Jan 15; 72(2):408-19. 
  24. Jin W, Chen BB, Li JY, Zhu H, Huang M, Gu SM, Wang QQ, Chen JY, Yu S, Wu J, Shao ZM*. TIEG1 inhibits breast cancer invasion and metastasis by inhibition of epidermal growth factor receptor (EGFR) transcription and the EGFR signaling pathway. Mol Cell Biol, 2012 Jan; 32(1):50-63.
  25. Chen AX, Yu KD, Fan L, Li JY, Yang C, Huang AJ, Shao ZM*. Germline genetic variants disturbing the Let-7/LIN28 double-negative feedback loop alter breast cancer susceptibility. PLoS Genet, 2011 Sep; 7(9):e1002259.
  26. Liu ZB, Hou YF, Zhu J, Hu DL, Jin W, Ou ZL, Di GH, Wu J, Shen ZZ, Shao ZM*. Inhibition of EGFR pathway signaling and the metastatic potential of breast cancer cells by PA-MSHA mediated by type 1 fimbriae via a mannose-dependent manner. Oncogene, 2010 May 20; 29(20):2996-3009.
  27. Feng LY, Ou ZL, Wu FY, Shen ZZ, Shao ZM*. Involvement of a novel chemokine decoy receptor CCX-CKR in breast cancer growth, metastasis and patient survival. Clin Cancer Res, 2009 May 1; 15(9):2962-70. 
  28. Fan L, Zheng Y, Yu KD, Liu GY, Wu J, Lu JS, Shen KW, Shen ZZ, Shao ZM*. Breast cancer in a transitional society over 18 years: trends and present status in Shanghai, China. Breast Cancer Res Treat, 2009 Sep; 117(2):409-16.
  29. Yu KD, Di GH, Yuan WT, Fan L, Wu J, Hu Z, Shen ZZ, Zheng Y, Huang W, Shao ZM*. Functional polymorphisms, altered gene expression and genetic association link NRH: quinone oxidoreductase 2 to breast cancer with wild-type p53. Hum Mol Genet, 2009 Jul 1; 18(13):2502-17.
  30. Yu KD, Di GH, Fan L, Wu J, Hu Z, Shen ZZ, Huang W, Shao ZM*. A functional polymorphism in the promoter region of GSTM1 implies a complex role for GSTM1 in breast cancer. FASEB J, 2009 Jul; 23(7):2274-87.
  31. Feng LY, Ou ZL, Wu FY, Shen ZZ and Shao ZM*. Involvement of a novel chemokine decoy receptor CCX-CKR in breast cancer growth, metastasis and patient survival. Clin Cancer Res, 2009; 15: 2962-2970.
  32. Wang J, Ou ZL, Hou YF, Luo JM, Shen ZZ, Ding J and Shao ZM*. Enhanced expression of Duffy antigen receptor for chemokines by breast cancer cells attenuates growth and metastasis potential. Oncogene, 2006 Nov 16; 25(54):7201-11.
 
复旦大学肿瘤研究所 通讯地址: 东安路270号2号楼1312室 64175590-5312 Email:fuci2012@126.com
Copyright 2013 shca.org.cn All rights reserved. 复旦大学肿瘤研究所 版权所有